Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Adjunctive Hyaluronic Acid Gel in Non-Surgical Periodontal Treatment of Patients With Diabetes Mellitus

2 de junho de 2026 atualizado por: Marmara University

The Effect of Hyaluronic Acid on Non-Surgical Periodontal Treatment in Patients With Diabetes Mellitus

The goal of this clinical trial is to evaluate whether the adjunctive use of hyaluronic acid (HA) improves periodontal healing in people with diabetes mellitus and periodontitis. The effects of HA on biomolecules and bacteria levels will be assessed during the follow-up period.

The main questions the study will answer are:

  • Will periodontal sites treated with non-surgical periodontal treatment (NSPT) plus HA gel show better clinical periodontal parameters than sites treated with only NSPT in patients with diabetes and periodontitis?
  • will HA gel have additional effect on reducing inflammation or collagen markers, and bacteria levels during follow-up?

Researchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.

Participants will:

  • provide recent HbA1c test results.
  • then, the participants will receive full-mouth NSPT then, randomization will be performed for the selected jaw for test sites. These two interproximal test sites will additionally receive HA application.
  • attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.

The GCF samples will be evaluated for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels and subgingival samples for periodontal pathogens.

Visão geral do estudo

Descrição detalhada

This study is a randomized controlled split-mouth clinical trial that investigates the clinical, biochemical, and microbiological effects of adjunctive Hyadent BG® gel application into selected interproximal periodontal pocket sites after non-surgical periodontal treatment (NSPT) in patients with diabetes mellitus (DM) and stage III/IV periodontitis.

Periodontitis is a chronic inflammatory disease characterized by the progressive destruction of the tooth-supporting tissues. DM is an important modifying factor for periodontal disease progression and treatment response. Hyperglycemia-related alterations in host immune response, collagen metabolism, microvascular function, and wound healing may contribute to increased periodontal inflammation and delayed periodontal healing. Therefore, adjunctive local approaches that may enhance the response to NSPT are clinically relevant in this patient population.

Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in periodontal tissues and the extracellular matrix. Because of its hydrophilic, viscoelastic, anti-inflammatory, and wound-healing properties, HA has been investigated as an adjunctive agent in periodontal therapy. In this study, HA gel will be applied locally into periodontal pockets after scaling and root planing to evaluate whether it provides additional benefit beyond NSPT alone.

The study will include a total of 23 patients with DM and Stage III/IV periodontitis who applied to the Department of Periodontology, Faculty of Dentistry, Marmara University. Eligible participants will receive detailed information regarding the study procedures, and written informed consent will be obtained prior to enrollment.

TREATMENT PROCEDURES

Before treatment, recent HbA1c and fasting plasma glucose (FPG) test results will be obtained. Two days before NSPT, radiographic and full-mouth clinical evaluations will be carried out to determine which jaw will be included in the study. Intraoral photographs will be taken, and impressions of the related jaw will be taken for stent fabrication. One day before NSPT, clinical measurements of the related sites with the stent will be repeated. NSPT will be completed in three sessions within two weeks. Before starting NSPT, baseline pooled gingival crevicular fluid (GCF) samples and then pooled subgingival microbiological samples will be collected sequentially from the related sites of the selected jaw. Then oral hygiene instructions will be provided, followed by full-mouth supragingival and subgingival scaling using ultrasonic and hand instruments in two weeks time. At the last session of NSPT, test sites (non-adjacent sites with ≥6 mm pocket depth) for adjunctive use of HA gel will be randomly determined by a toss of a coin from the selected jaw, and HA will be applied subgingivally.

All patients will be followed up at the 1-, 3-, and 6-month intervals.

Periodontal Clinical Measurements

At baseline and at 1, 3, and 6 months, full-mouth clinical measurements will be performed. Periodontal clinical measurements will be recorded at six sites per tooth-mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual-using a Williams periodontal probe (Hu-Friedy).

Plaque Index (PI): Dental plaque accumulation will be assessed after air drying the teeth using a periodontal probe and visual inspection, according to the PI system developed by Silness and Löe.

Gingival Index (GI): The gingival inflammatory status will be assessed using the GI developed by Löe and Silness.

Probing Depth (PD): PD will be measured as the distance from the free gingival margin to the base of the periodontal pocket by inserting the periodontal probe to the pocket base.

Clinical Attachment Level (CAL): CAL will be recorded by measuring the distance from the cemento-enamel junction to the base of the pocket.

Bleeding on Probing (BOP) (%): BOP will be assessed 25-30 seconds after pocket probing. Sites showing bleeding will be recorded as positive (+), while those without bleeding will be recorded as negative (-).

Collection of GCF and Subgingival Microbiological Samples At baseline, both GCF and pooled subgingival microbiological samples will be collected after clinical measurements from test and control sites, but at follow-up visits (1st, 3rd, and 6th months) prior to clinical measurements. Before sampling, supragingival plaque will be carefully removed, then the test (n=2) and control (n=2) sites will be isolated from saliva using cotton rolls and dried. First, GCF samples will be collected. Periopaper strips will be inserted 1-2 mm into the periodontal pocket and left in place for 30 seconds at the selected sites. GCF volume will be measured. Following GCF sampling, subgingival microbiological sampling will be carried out by inserting sterile paper points (#30) to the base of the periodontal pockets and kept in place for 10 seconds. All GCF and the subgingival microbiological samples will be stored at -80°C until the day of analysis. GCF samples will be analyzed for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels using commercially available enzyme-linked immunosorbent assay kits. IL-34 will be assessed as a marker related to local inflammatory activity, and β-CTX will be assessed as a marker of type I collagen degradation.

Quantification of A. actinomycetemcomitans, F. nucleatum, P. gingivalis, T. forsythia, and P. intermedia in subgingival microbiological samples will be performed using real-time polymerase chain reaction.

Statistical Analysis

Statistical analyses will be performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA). A confidence level of 95% will be adopted for all analyses, and a p value of less than 0.05 will be considered statistically significant.

Due to the split-mouth study design, test and control sites within the same individual will be treated as paired samples.

Descriptive statistics for clinical parameters (PI, GI, BOP, PD, and CAL) and biochemical markers (IL-34 and β-CTX) will be expressed as mean ± standard deviation, median, and minimum-maximum values.

The normality of data distribution will be assessed using the Shapiro-Wilk test. For normally distributed variables, within-group comparisons over time (baseline, 1 month, 3 months and 6 months) will be analyzed using one-way repeated measures analysis of variance (ANOVA). When a statistically significant difference is detected, pairwise comparisons will be performed using the Tukey post hoc test.

Comparisons between test and control sites will be conducted using the paired samples t-test.

For variables that do not follow a normal distribution, within-group comparisons over time will be analyzed using the Friedman two-way analysis of variance. When significant differences are observed, pairwise comparisons will be performed using the Wilcoxon signed-rank test.

Between-group comparisons for non-normally distributed variables will be performed using the Mann-Whitney U test.

Correlations between clinical, biochemical, and microbiological variables will be evaluated using Spearman's correlation analysis. Variables found to be significant will be further analyzed using multiple linear regression to assess their independent effects.

Tipo de estudo

Intervencional

Inscrição (Estimado)

23

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Istanbul, Turquia (Türkiye)
        • Department of Periodontology, Faculty of Dentistry, Marmara University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Individuals who sign the informed consent form
  • Participants diagnosed with diabetes mellitus (HbA1c %7-7.9)
  • Participants without any systemic disease other than DM
  • Participants diagnosed with Stage III or Stage IV periodontitis
  • Nonsmokers
  • Participants with at least 15 natural teeth present in the mouth (excluding third molars)
  • Participants in either of the jaws, in both quadrants, having two non-adjacent interproximal sites with probing depth and clinical attachment level ≥6 mm with no caries, restorations or furcation involvement

Exclusion Criteria:

  • Individuals who do not sign the informed consent form
  • Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis
  • Participants have received any periodontal treatment within 6 months prior to the study
  • Participants who have used antibiotics within the last 3 months
  • Smokers
  • Participants who are pregnant or lactating

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Test
Non-surgical periodontal treatment and Hyaluronic Acid gel
Raspagem e alisamento radicular é um tratamento padrão-ouro convencional para a periodontite. Como parte deste procedimento, a placa subgengival e o tártaro são removidos e as superfícies radiculares são aplainadas.
Hyaluronic acid will be locally applied to periodontal pockets as an adjunct to non-surgical periodontal therapy, aiming to support periodontal healing. After completion of scaling and root planing, the material will be delivered subgingivally to designated test sites in a split-mouth design.
Outro: Control
Non-surgical periodontal treatment alone
Raspagem e alisamento radicular é um tratamento padrão-ouro convencional para a periodontite. Como parte deste procedimento, a placa subgengival e o tártaro são removidos e as superfícies radiculares são aplainadas.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Clinical Attachment Level
Prazo: Baseline, 1, 3 and 6 months after NSPT
Clinical attachment level (CAL) will be measured in millimeters using a periodontal probe. The change in CAL will be calculated as the difference between baseline and follow-up measurements. A decrease in CAL indicates an improvement in periodontal attachment.
Baseline, 1, 3 and 6 months after NSPT
Change in Probing Depth
Prazo: Baseline, 1, 3 and 6 months after NSPT
Probing depth will be measured around each tooth by recording the distance in millimeters from the gingival margin to the bottom of the pocket at 6 locations (mesiobuccal, mid-buccal, distobuccal, mesiopalatal, mid-palatal, distopalatal).
Baseline, 1, 3 and 6 months after NSPT

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change of Bleeding on Probing (%)
Prazo: Baseline, 1, 3 and 6 months after NSPT
Possible score for bleeding on probing range from %0 (no sites with bleeding on probing) to %100 (all sites with bleeding on probing). Higher scores mean worse outcome.
Baseline, 1, 3 and 6 months after NSPT
Change in Plaque Index
Prazo: Baseline, 1, 3 and 6 months after NSPT
Possible scores for Plaque Index range from 0 (no plaque) to 3 (visible plaque all around the tooth). Higher scores mean a worse outcome.
Baseline, 1, 3 and 6 months after NSPT
Change in Gingival Index
Prazo: Baseline, 1, 3 and 6 months after NSPT
Possible score for Gingival Index range from 0 (healthy gingiva) to 3 (severe gingivitis with bleeding). Higher scores mean worse outcome.
Baseline, 1, 3 and 6 months after NSPT
Change in GCF IL-34 Levels
Prazo: Baseline, 1, 3 and 6 months after NSPT
Change in IL-34 levels from baseline to 1, 3 and 6 months after NSPT
Baseline, 1, 3 and 6 months after NSPT
Change in GCF β-CTX Levels
Prazo: Baseline to 1, 3 and 6 months after NSPT
Change in β-CTX levels from baseline 1, 3 and 6 months after NSPT
Baseline to 1, 3 and 6 months after NSPT
Change in level of Porphyromonas gingivalis
Prazo: Baseline, 1, 3 and 6 months after NSPT
Change in Porphyromonas gingivalis levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
Baseline, 1, 3 and 6 months after NSPT
Change in level of Fusobacterium nucleatum
Prazo: Baseline, 1, 3 and 6 months after NSPT
Change in Fusobacterium nucleatum levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
Baseline, 1, 3 and 6 months after NSPT
Change in level of Aggregatibacter actinomycetemcomitans
Prazo: Baseline, 1, 3 and 6 months after NSPT
Change in A. actinomycetemcomitans levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
Baseline, 1, 3 and 6 months after NSPT
Change in level of Tanerella forsythia
Prazo: Baseline, 1, 3 and 6 months after NSPT
Change in Tanerella forsythia levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
Baseline, 1, 3 and 6 months after NSPT
Change in level of Prevotella intermedia
Prazo: Baseline, 1, 3 and 6 months after NSPT
Change in Prevotella intermedia levels in subgingival microbiological samples from baseline to 1, 3 and 6 months after NSPT.
Baseline, 1, 3 and 6 months after NSPT

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de junho de 2026

Conclusão Primária (Estimado)

1 de julho de 2028

Conclusão do estudo (Estimado)

1 de julho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de junho de 2026

Primeira postagem (Real)

8 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

8 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever